INKT MiNK Therapeutics
MiNK Therapeutics earnings company data as of 4:47 AM ET 10/22
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
2 periods, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 13 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by INKT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $47K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Barbara Ryan DirectorSale$19K 1,500 shares at $12.76 6.4% of stakeTraded Jun 4 Filed Jun 5
-
Barbara Ryan DirectorSale$22K 1,500 shares at $14.70 6.8% of stakeTraded Mar 9–10 Filed Mar 11
-
Barbara Ryan DirectorSale$5,426 500 shares at $10.85 2.2% of stakeTraded Feb 27–Mar 2 Filed Mar 4
Also filed in the last 12 months, not counted as buying or selling: 22 stock grants, 1 share withholding for taxes, 1 option exercise, and 1 sale to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 13 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.02 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.